Current progress in innovative engineered antibodies

Abstract

As of May 1, 2017, 74 antibody-based molecules have been approved by a regulatory authority in a major market. Additionally, there are 70 and 575 antibodybased molecules in phase III and phase I/II clinical trials, respectively. These total 719 antibody-based clinical stage molecules include 493 naked IgGs, 87 antibodydrug conjugates, 61 bispecific antibodies, 37 total Fc fusion proteins, 17 radioimmunoglobulins, 13 antibody fragments, and 11 immunocytokines. New uses for these antibodies are being discovered each year. For oncology, many of the exciting new approaches involve antibody modulation of T-cells. There are over 80 antibodies in clinical trials targeting T cell checkpoints, 26 T-cellredirected bispecific antibodies, and 145 chimeric antigen receptor (CAR) cell-based candidates (all currently in phase I or II clinical trials), totaling more than 250 T cell interacting clinical stage antibody-based candidates. Finally, significant progress has been made recently on routes of delivery, including delivery of proteins across the blood-brain barrier, oral delivery to the gut, delivery to the cellular cytosol, and gene- and viral-based delivery of antibodies. Thus, there are currently at least 864 antibody-based clinical stage molecules or cells, with incredible diversity in how they are constructed and what activities they impart. These are followed by a next wave of novel molecules, approaches, and new methods and routes of delivery, demonstrating that the field of antibody-based biologics is very innovative and diverse in its approaches to fulfill their promise to treat unmet medical needs.

Key words： antibody clinical candidates; engineered antibodies; chimeric antigen receptors

References

1 Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37:13–25

2 Abulrob A, Sprong H, Henegouwen E, Van Bergen P, Stanimirovic D (2005) The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 95:1201–1214

3 Achkar T, Tarhini AA (2017) The use of immunotherapy in the treatment of melanoma. J Hematol Oncol 10:88.

4 Adam VS, Crosariol M, Kumar S, Ge MO, Czack SE, Roy S, Haczku A, Tretiakova A, Wilson JM (2014) Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. Clin Vaccine Immunol 21:1528–1533

5 Adelfinger M, Bessler S, Frentzen A, Cecil A, Langbein-Laugwitz J, Gentschev I, Szalay AA (2015) Preclinical testing oncolytic vaccinia virus strain GLV-5b451 expressing an anti-VEGF singlechain antibody for canine cancer therapy. Viruses 7:4075–4092

6 Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CHT, Tutt A, Beers SA (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117:4519–4528

7 Anthony RM, Ravetch JV (2010) A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 30(Suppl 1):S9–14

8 Antonia SJ, Vansteenkiste JF, Moon E (2016) Immunotherapy: beyond anti–PD-1 and anti–PD-L1 therapies. ASCO Educ Book 2016:e450–e458

9 Baeuerle PA, Reinhardt C, Kufer P (2008) BiTE: a new class of antibodies that recruit T-cells. Drugs Future 33:137–147

10 Baker K, Qiao S-W, Kuo T, Kobayashi K, Yoshida M, Lencer WI, Blumberg RS (2009) Immune and non- immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol 31:223–226

11 Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, An DS, Baltimore D (2014) Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 20:296–300

12 Barnhart BC, Quigley M (2017) The role of Fc-FcγR interactions in the anti-tumor activity of therapeutic antibodies. Immunol Cell Biol 95:340–346

13 Beck A, Goetsch L, Dumontet C, Corvaïa N (2017) Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov 16:315–337

14 Beerli RR, Hell T, Merkel AS, Grawunder U (2015) Sortase enzymemediated generation of site- specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS ONE 10:e0131177.

15 Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M (1988) Single-chain antigen-binding proteins. Science 242:423–426

16 Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P (2010) Epitope distance to the target cell membrane and antigen size determine the potency of T cellmediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 59:1197–1209

17 Boado RJ, Pardridge WM (2017) Brain and organ uptake in the rhesus monkey in vivo of recombinant iduronidase compared to an insulin receptor antibody-iduronidase fusion protein. Mol Pharm 14:1271–1277

18 Boado RJ, Zhang Y, Zhang Y, Pardridge WM (2007) Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng 96:381–391

19 Boado RJ, Hui EK, Lu JZ, Pardridge WM (2012)Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab Dispos 40:2021–2025

20 Boado RJ, Hui EK-W, Lu JZ, Pardridge WM (2014) Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in rhesus monkeys. Biotechnol Bioeng 111:2317–2325

21 Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 23:403–411

22 Bommareddy PK, Patel A, Hossain S, Kaufman HL (2017) Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol 18:1–15

23 Borrok MJ, Mody N, Lu X, Kuhn M, Wu H, Dall’Acqu WF, Tsui P (2017) An ‘Fc silenced’ IgG1 format with extended half-life designed for improved stability. J Pharm Sci.

24 Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ (2014) ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother 63:437–448

25 Bostrom J, Yu S-F, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323:1610–1614

26 Brack S, Attinger-Toller I, Schade B, Mourlane F, Klupsch K, Woods R, Hachemi H, von der Bey U, Koenig- Friedrich S, Bertshinger J, Grabulovski D (2014) A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action. Mol Cancer Ther 13:2030–2039

27 Brennan M, Davison PF, Paulus H (1985) Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229:81–83

28 Brezski RJ, Georgiou G (2016) Immunoglobulin isotype knowledge and application to Fc engineering. Curr Opin Immunol 40:62–69

29 Brinkmann U, Kontermann RE (2017) The making of bispecific antibodies. mAbs 9:182–212

30 Cancro MP, D’Cruz DP, Khamasta MA (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Investig 119:1066–1073

31 Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature 337:525–531

32 Carotta S (2016) Targeting NK cells for anticancer immunotherapy: clinical and preclinical approaches. Front Immunol 7:152.

33 Carvalho S, Levi-Schaffer F, Sela M, Yarden Y (2016) Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anticancer antibodies: IUPHAR Review 18. Br J Pharmacol 173:1407–1424

34 Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM (2012) Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 287:11090–11097

35 Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H (2010) Structural and functional characterization of the trifunctional antibody catumaxomab. mAbs 2:309–319

36 Chikuma S, Kanamori M, Mise-Omata S, Yoshimura A (2017) Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy. Cancer Sci 108:574–580

37 Chmielewski M, Hombach AA, Abken H (2014) Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 257:83–90

38 Choi D-K, Bae J, Shin S-M, Shin J-Y, Kim S, Kim Y-S (2014) A general strategy for generating intact, full- length IgG antibodies that penetrate into the cytosol of living cells. mAbs 6:1402–1414

39 Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, doseescalating trial. Rheumatol 41:1133–1137

40 Chromikova V, Mader A, Hofbauer S, Göbl C, Madl T, Gach JS, Bauenfried S, Furtmüller PG, Forthal DN, Mach L (2015) Introduction of germline residues improves the stability of anti-HIV mAb 2G12- IgM. Biochim Biophys Acta 1854:1536–1544

41 Clark RH, Latypov RF, De Imus C, Carter J, Wilson Z, Manchulenko K, Brown ME, Ketchem RR (2014) Remediating agitationinduced antibody aggregation by eradicating exposed hydrophobic motifs. mAbs 6:1540–1550

42 Coloma MJ, Morrison SL (1997) Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15:159–163

43 Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP (2016) Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions. J Immunol 197:1762–1775

44 Dall’Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171–5180

45 Dall’Acqua WF, Kiener PA, Wu H (2006) Properties of human IgG1 engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514–23524

46 Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ (2015) Balancing charge in the complementarity determining regions of humanized mAbs without affecting pI reduces non-specific binding and improve pharmacokinetics. mAbs 7:483–493

47 Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ (2007) Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 34:2204–2210

48 de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie C, Wang G (2016) A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol 14: e1002344.

49 Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EEM, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ (2013) Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Trans Med 5:207ra144.

50 Devanaboyina SC, Lynch SM, Ober RJ, Ram S, Kim D, Puig-Canto A, Breen S, Kasturirangan S, Fowler S, Peng L (2013) The effect of pH dependence of antibody–antigen interactions on subcellular trafficking dynamics. mAbs 5:851–859

51 Drake PM, Rabuka D (2015) An emerging playbook for antibodydrug conjugates: lessons learned from the laboratory and clinic suggest a strategy for improving efficacy and safety. Curr Opin Chem Biol 28:174–180

52 Du T, Shi G, Li YM, Zhang JF, Tian HW, Wei YQ, Deng H, Yu DC (2014) Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther 21:340–348

53 Dutcher JP (2002) Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology 16(Suppl 13):4–10

54 Dyck L, Mills KHG (2017) Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. doi:10.1002/eji.201646875

55 Egan TJ, Diem D, Weldon R, Neumann T, Meyer S, Urech DM (2016) Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments. mAbs 9:68–84

56 Eigenbrot C, Fuh G (2013) Two-in-one antibodies with dual action Fabs. Curr Opin Chem Biol 17:400–405

57 Ellebæk S, Brix S, Grandal M, Lantto J, Horak ID, Kragh M, Poulsen TT (2016) Pan-HER—An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers. Int J Cancer 139:2095–2105

58 Erster O, Thomas JM, Hamzah J, Jabaiah AM, Getz JA, Schoep TD, Hall SS, Ruoslahti E, Daugherty PS (2012) Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release 161:804–812

59 Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720–724

60 Esparis-Ogando A, Montero JC, Arribas J, Ocana A, Pandiella A (2016) Targeting the EGF/HER ligand- receptor system in cancer. Curr Pharm Des 22:5887–5898

61 Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, June CH, Alemany R (2017) Oncolytic adenoviral delivery of an EGFR-targeting T cell engager improves antitumor efficacy. Cancer Res 77:2052–2063

62 Farrington GK, Caram-Salas N, Haqqani AS, Brunette E, Eldredge J, Pepinsky B, Antognetti G, Baumann E, Ding W, Garber E (2014) A novel platform for engineering blood-brain barriercrossing bispecific biologics. FASEB J 28:4764–4778

63 Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of golgi enzyme localization domain and co-expression of heterologous beta 1,4-N-acetylglucosaminyltransferase III and golgi alpha- mannosidase II. Biotechnol Bioeng 93:851–861

64 Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F (2015) Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol 34:54–187

65 Fuchs SP, Desrosiers RC (2016) Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Methods Clin Dev 3:16068.

66 Fuchs SP, Martinez-Navio Gao G, Desrosiers RC (2016) Recombinant AAV vectors for enhanced expression of authentic IgG. PLoS ONE 11:e0158009.

67 Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM, Wunderlich JR (1990) Refocusing the immune system to react with human tumors by targeting human lymphocytes with bispecific antibodies. Dev Biol Stand 71:33–42

68 Giraud A, Ataman-Önal Y, Battail N, Piga N, Brand D, Mandrand B, Verrier B (1999) Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. J Virol Methods 79:75–84

69 Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M (2013) Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122:3482–3491

70 Gorovits B, Krinos-Fiorotti C (2013) Proposed mechanism of offtarget toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother 62:217–223

71 Gray KA, Yates B, Seal RL, Wright MW, Bruford EA (2015) Genenames.org: the HGNC resources in 2015. Nucleic Acids Res 43(Database issue):D1079–D1085.

72 Greenwood J, Clark M, Waldmann H (1993) Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 23:1098–1104

73 Greig JA, Calcedo R, Grant RL, Peng H, Medina-Jszek CA, Ahonkhai O, Qin Q, Roy S, Tretiakova AP, Wilson JM (2016) Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. Vaccine 34:6323–6329

74 Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, Sweet H, Foltz IN, Wittekind M, Yan W (2010) Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 285:19637–19646

75 Ha J-H, Kim J-E, Kim Y-S (2016) Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins. Front Immunol.

76 Hale M, Mesojednik T, Romano Ibarra GS, Sahni J, Bernard A, Sommer K, Scharenberg AM, Rawlings DJ, Wagner TA (2017) Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells. Mol Ther 25:570–579

77 Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20:264–269

78 Harris SJ, Brown J, Lopez J, Yap TA (2016) Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med.

79 Hawkins RE, Russel SJ, Winter G (1992) Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 226:889–896

80 Hemmerle T, Neri D (2014) The antibody-based targeted delivery of interleukin-4 and 23 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int J Cancer 134:467–477

81 Hernandez-Hoyos G, Sewell T, Bader R, Bannink J, Chenault RA, Daugherty M, Dasovich M, Fang H, Gottschalk R, Kumer J (2016) MOR209/ES414, a novel bispecific antibody targeting PSMA For the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther 15:2155–2165

82 Hess J, Ruf P, Lindhofer H (2012) Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity. Future Oncol 8:73–85

83 Hofman C, Seefried L, Jakob F (2016) Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia. Drugs Today (Barc) 52:271–285

84 Holliger P, Winter G (1997) Diabodies: small bispecific antibody fragments. Cancer Immunol Immunother 45:128–130

85 Holliger P, Prospero T, Winter G (1993) “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444–6448

86 Hughes C, Sette A, Seed M, D’Acquisto F, Manzo A, Vincent TL, Lim NH, Nissim A (2014) Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency. Arthritis Res Ther 16:R151.

87 Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný M, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879–5883

88 Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y (2010a) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 28:1203–1207

89 Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y (2010b) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23:385–392

90 Igawa T, Maeda A, Haraya K, Tachibana T, Iwayanagi Y, Mimoto F, Higuchi Y, Ishii S, Tamba S, Hironiwa N (2013) Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS One 8:e63236

91 Igawa T, Haray K, Hattori K (2016) Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. Immunol Rev 270:132–151

92 Ihospice F, Delphine B, Belmant C, Patrick D, Aristeidis C, Fischer E, Laurent G, Bonnafus C, Viaud N, Represa A (2015) Sitespecific conjugation of monomethyl auristatin E to anti-CD30 antibodies improves their pharmacokinetics and therapeutic index in rodent models. Mol Pharm 12:1863–1871

93 Ilan Y, Gingis-Velitski S, Ben Ya’aco A, Shabbat Y, Zolotarov L, Almon E, Shaaltiel Y (2017) A plant cell- expressed recombinant anti-TNF fusion protein is biologically activity in the gut and alleviates immune- mediated hepatitis and colitis. Immunobiol 222:544–551

94 Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B (2010) Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 399:436–449

95 Jones PT, Dear PH, Foote J, Neuberger M, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522–525

96 Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925–932

97 Kanda Y, Yamane-Ohnuki N, Sakai N, Yamano K, Nakano R, Inoue M, Misaka H, Iida S, Wakitani M, Konno Y, Yano K, Shitara K, Hosoi S, Satoh M (2006) Comparison of cell lines for stable production of fucose- negative antibodies with enhanced ADCC. Biotechnol Bioeng 94:680–688

98 Kim J-S, Choi D-K, Shin J-Y, Shin S-M, Park S-W, Cho H-S, Kim Y-S (2016) Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape. J Controlled Rel 235:165–175

99 Kim BJ, Kim JH, Kim HS (2017) Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: a meta-analysis and review. Oncotarget.

100 Kinder M, Greenplate AR, Grugan K, Bannish G, Perpetua M, Jordan RE, Strohl WR, Brezski RJ (2013) Engineered proteaseresistant antibodies with selectable cell-killing functions. J Biol Chem 288:30843–30854

101 Kingwell K (2017) CAR T therapies drives into new terrain. Nat Rev Drug Discov 16:301–304

102 Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, von der Lieth C-W, Matys ER, Little M (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 293:41–56

103 Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W (2012) Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs 4:653–663

104 Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M (2017) Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology 6: e1277306

105 Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, Fahrner C, Schmitt D, Gantzer M, Remy-Ziller C (2016) Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor- growth inhibition. Oncoimmunology 5:e1220467

106 Konkar A, Suckow A, Hummer T, Chodorge M, Celeste A, Hornigold D, Naylor J, Jenkinson L, Feigh M, Agoram B (2016) MEDI4166: a PCSK9 Ab-GLP-1 fusion molecule that elicits robust antidiabetic and antihyperlipidaemic effects in rodents and non-human primates EASD. Abstract #1107

107 Kontermann RE (2012) Dual targeting strategies with bispecific antibodies. Mabs 4:182–197

108 Kontermann RE, Brinkmann U (2015) Bispecific antibodies. Drug Discov Today 20:838–847

109 La Merie Publishing (2017) 2016 sales of recombinant therapeutic antibodies & proteins. Weikersheim 97990, Germany

110 Labrijn AF, Aalberse RC, Schuurman J (2008) When binding is enough: nonactivating antibody formats. Curr Opin Immunol 20:479–485

111 Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ (2013) Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA 110:5145–5150

112 Lalazar G, Mizrahi M, Turgeman I, Adar T, Ya’acov AB, Shabat Y, Nimer A, Hemed N, Zolotarovya L, Lichtenstein Y (2015) Oral administration of OKT3 Mab to patients with NASH, promotes regulatory T-cell induction, and alleviates insulin resistance: results of a phase IIa blinded placebo- controlled trial. J Clin Immunol 35:399–407

113 Lazar AC, Wang L, Blättler WA, Amphlett G, Lambert JM, Zhang W (2005) Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun Mass Spectrom 19:1806–1814

114 Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Veilmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103:4005–4010

115 Lee KJ, Chow V, Weissman A, Tulpule S, Aldoss I, Akhtari M (2016) Clinical use of blinatumomab for B- cell acute lymphoblastic leukemia in adults. Ther Clin Risk Manag 12:1301–1310

116 Leung KM, Batey S, Rowlands R, Isaac SJ, Jones P, Drewett V, Carvalho J, Gaspar M, Weller S, Medcalf M, Wydro MM, Pegram R, Mudde GC, Bauer A, Moulder K, Woisetschläger M, Tuna M, Haurum JS, Sun H (2015) A HER2-specific modified Fc fragment (Fcab) induces antitumor effects through degradation of HER2 and apoptosis. Mol Ther 23:1722–1733

117 Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR (2002) Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 76:8769–8775

118 Li J, Ji J, Holmes LM, Burgin KE, Barton LB, Yu X, Wagner TE, Wei Y (2004) Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor. Cancer Gene Ther 11:363–370

119 Li B, Tesar D, Boswell A, Cahaya H, Wong A, Zhang J, Gloria Meng Y, Eigenbrot C, Pantua H, Diao J (2014) Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. mAbs 6:1255–1264

120 Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, Nicholas ND, Okeley NM, Lyon RP, Benjamin DR, Law C-L (2016) Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res 76:2710–2719

121 Liikanen I, Tahtinen S, Guse K, Gutmann T, Savola P, Oksanen M, Kanerva A, Hemminki A (2016) Oncolytic adenovirus expressing monoclonal antibody trastuzumab for treatment of HER2-positive cancer. Mol Cancer Ther 15:2259–2269

122 Lim WA, June CH (2016) The principles of engineering immune cells to treat cancer. Cell 168:724–740

123 Lim SI, Lukianov CI, Champion JA (2017) Self-assembled protein nanocarrier for intracellular delivery of antibody. J Controlled Rel 249:1–10

124 Limberis MP, Adam VS, Wong G, Gren J, Kobasa D, Ross TM, Konbinger GP, Tretiakova A, Wilson JM (2013) Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Trans Med 5 (187):187ra72

125 Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA (2015) Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol 89:6685–6694

126 Liu L, Lam CK, Long V, Widjaja L, Yang Y, Li H, Jin L, Burke S, Gorlatov S, Brown J (2017) MGD011, a CD19 x CD3 dualaffinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies. Clin Cancer Res 23:1506–1518

127 Llewelyn MB, Hawkins RE, Russell SJ (1992) Discovery of antibodies. BMJ 305:1269–1272

128 Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes J-M, Zhang Y, Lin YL, Chung S, Dennis MS, Joy Y (2017) Effector attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem 292:3900–3909

129 Lönn P, Kacsinta AD, Cui X-S, Hamil AS, Kaulich M, Gogoi K, Dowdy SF (2016) Enhancing endosomal escape for intracellular delivery of macromolecular biologic therapeutics. Nat Sci Rep 8 (6):32301.

130 Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao J-A, Matsushita H, Liu Y, Postnikova EN, Ork BL (2016) Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS- CoV in vivo. Sci Trans Med 8:326ra21.

131 Lum LG, Thakur A (2011) Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs 25:365–379

132 Mack M, Riethmüller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92:7021–7025

133 MacLeod DT, Antony J, Martin AJ, Moser RJ, Hekele A, Wetzel KJ, Brown AW, Triggiano MA, Hux JA, Pham CD (2017) Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol Ther 25:949–961

134 Madrenas J, Chau LA, Teft WA, Wu PW, Jussif J, Kasaian M, Carreno BM, Ling V (2004) Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fc ligand. J Immunol 172:5948–5956

135 Malphettes L, Freyvert Y, Chang J, Liu PQ, Chan E, Miller JC, Zhou Z, Nguyen T, Tsai C, Snowden AW, Collingwood TN, Gregory PD, Cost GJ (2010) Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. Biotechnol Bioeng 106:774–783

136 Marschall ALJ, Zhang C, Frenzel A, Schirrmann T, Hust M, Perez F, Dübel S (2014) Delivery of antibodies to the cytosol. Debunking the myths. mAbs 6:943–956

137 Matsushita H, Sano A, Wu H, J-aJiao, Kasinathan P, Sullivan EJ, Wang Z, Kuroiwa Y (2014) Triple immunoglobulin gene knockout transchromosomic cattle: bovine lambda cluster deletion and its effect on fully human polyclonal antibody production. PLoS ONE 9:e90383.

138 Matsushita H, Sano A, Wu H, Wang Z Jiao, J-a, Kasinathan P, Sullivan EJ, Kuroiwa Y (2015) Species- specific chromosome engineering greatly improves fully human polyclonal antibody production profile in cattle. PLoS ONE 10:e0130699.

139 McCracken MN, Cha AC, Weissman IL (2015) Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 “don’t eat me” signals. Clin Cancer Res 21:3597–3601

140 Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16:677–681

141 Millan JL, Narisawa S, Lemire I, Loisel TP, Boileau G, Leonard P, Gramatikova S, Terkeltaub R, Pleshko Camacho NMcKee MD (2008) Enzyme replacement therapy for murine hypophosphatasia. J Bone Min Res 23:777–787

142 Milstein C, Cuello AC (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305:537–540

143 Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, Geisbert TW (2016) Passive immunotherapy: assessment of convalescent serum against ebola virus makona infection in nonhuman primates. J Infect Dis 214(Suppl 3):S367–S374

144 Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y (2011) Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B- cell lymphoma. Blood 117:4542–4551

145 Moretti P, Skegro D, Ollier R, Wassmann P, Aebischer C, Laurent T, Schmid-Printz M, Giovannini R, Blein S, Bertschinger M (2013) BEAT® the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs. BMC Proc 7(Suppl 6):O9.

146 Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851–6855

147 Mueller JP, Giannoni MA, Hartman SL, Elliott EA, Squinto SP, Mathis LA, Evans MJ (1997) Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol Immunol 34:441–452

148 Neri D, Sondel PM (2016) Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol 40:96–102

149 Nesspor TC, Raju TS, Chin C-N, Vafa O, Brezski RJ (2012) Avidity confers FcγR binding and immune effector fuction to aglycosylated IgG1. J Mol Recognit 25:147–154

150 Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC (2014) Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81:49–60

151 Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inoges S, Melero I, Berraondo P (2017) Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol 95:347–355

152 Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR (2014) Sitespecific antibody drug conjugates for cancer therapy. mAbs 6:34–45

153 Park JH, Brentjens RJ (2010) Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 9:277–288

154 Pasche N, Wuhlfard S, Pretto F, Carugati E, Neri D (2012) The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res 18:4092–4103

155 Penichet ML, Morrison SL (2001) Antibody–cytokine fusion proteins for the therapy of cancer. J Immunol Methods 248:91–101

156 Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM (2014) Antibody-drug conjugates: current status and future directions. Drug Disc Today 19:869–981

157 Polu KR, Lowman HB (2014) Probody therapeutics for targeting antibodies to diseased tissue. Expert Opin Biol Ther 14:1049–1053

158 Poul M-A, Becerril B, Nielsen UB, Morisson P, Marks JD (2000) Selection of tumor-specific internalizing antibodies form phage libraries. J Mol Biol 301:1149–1161

159 Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86:10029–10033

160 Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ (2017) Optimized T-cell receptormimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen. Leukemia.

161 Raju TS, Strohl WR (2013) Potential therapeutic roles for antibody mixtures. Expert Opin Biol Ther 13:1347–1352

162 Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y (2017a) Multiplex genome editing to generate universal CAR Tcells resistant to PD-1 inhibition. Clin Cancer Res 23:2255–2266

163 Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y (2017b) A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 8:17002–17011

164 Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA (2015) A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits Tcells for the potent lysis of CD19(+) tumor cells. mAbs 7:584–604

165 Ridgeway JB, Presta LG, Carter P (1996) ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9:617–621

166 Robbie GJ, Criste R, Dall’acqua WF, Jensen K, Patel NK, Losonsky GA, Griffen MP (2013) A novel investigational Fc-modified humanized antibody, motavizumab-YTE, has an extended halflife in healthy adults. Antimicrob Agents Chemother 57:6147–6153

167 Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725

168 Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, Jin M, O’Sullivan C, Cummins E, Lambert M (2016) Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer. Antibodies 5:6.

169 Rother RP, Rollins SA, Mojcik CJ, Brodsky RJ, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256–1264

170 Ruella M, Gill S (2015) How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. Expert Opin Biol Ther 15:761–766

171 Ruella M, June CH (2016) Chimeric antigen receptor Tcells for B cell neoplasms: choose the right CAR for you. Curr Hematol Malig Rep 11:368–384

172 Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP (2013) Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology 446:268–275

173 Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T (2013) Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of Factor VIII cofactor activity. PLoS ONE 8:e57479.

174 Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M (2013) Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncol 9:527–539

175 Schirdewahn T, Grabowski J, Sekyere SO, Bremer B, Wranke A, Lunemann S, Schlaphoff V, Kirschner J, Hardtke S, Manns MP (2017) The third signal cytokine IL-12 rather than immune checkpoint inhibitors contribute to the functional restoration of hepatitis D virus-specific T-cells. J Infect Dis 215:139–149

176 Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S (2005) Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65:2882–2889

177 Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E (2016) Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Prot Eng Des Sel 29:457–466

178 Schnepp BC, Johnson PR (2014a) Adeno-associated virus delivery of broadly neutralizing antibodies. Curr Opin HIV AIDS 9:250–256

179 Schnepp BC, Johnson PR (2014b) Vector-mediated in vivo antibody expression. Microbiol Spect 2(4):AID-0016–2014.

180 Seeliger D, Schulz P, Litzenburger T, Spitz J, Hoerer S, Blech M, Enenkel B, Studts JM, Garidel P, Karow AR (2015) Boosting antibody developability through rational sequence optimization. mAbs 7:505–515

181 Sharkey RM, Rossi EA, Chang C-H, Goldenberg DM (2010) Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies. Cancer Biother Radiopharm 25:1–12

182 Shi Y, Fan X, Deng H, Brezski RJ, Rycyzyn M, Jordan RE, Strohl WR, Zou Q, Zhang N, An Z (2015) Trastuzumab triggers phagocytic killing of high HER2 cancer cells by interaction with FcγRIV on immune cells. J Immunol 194:4379–4386

183 Shields RL, Namenuk AK, Hog K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591–6604

184 Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SH, Presta LG (2002) Lack of fructose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma Rlll and antibody- dependent cellular toxicity. J Biol Chem 277:26733–26740

185 Siegmund V, Piater B, Zakeri B, Eichhorn T, Fischer F, Deutsch C, Becker S, Toleikis L, Hock B, Betz UAK, Kolmar H (2016) Spontaneous isopeptide bond formation as a powerful tool for engineering site- specific antibody-drug conjugates. Sci Rep 6:39291.

186 Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W, Schlereth B, Locher M, Bertschinger J, Grabulovski D (2016) Discovery and characterization of COVA322, a clinical stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. mAbs 8:141–149

187 Singh AP, Sharma S, Shah DK (2016) Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn 43:567–582

188 Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J, Principio J, MacDonald D, Kantrowitz J, Papadopoulos N, Stahl N, Yancopoulos GD, Thurston G, Davis S (2015) A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 5:17943

189 Smith AJ, Oertle J, Warren D, Prato D (2016) Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective. J Cell Immunol 2:59–68

190 Sondermann P, Szymkowski DE (2016) Harnessing Fc receptor biology in the design of therapeutic antibodies. Curr Opin Immunol 40:78–87

191 Spiess C, Zhai Q, Carter PJ (2015) Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 67:95–106

192 Stewart MP, Sharei A, Ding X, Sayay G, Langer R, Jensen KF (2016) In vitro and ex vivo strategies for intracellular delivery. Nature 538:183–192

193 Storz U (2014) Rituximab. How approval history is reflected by a corresponding patent filing strategy. mAbs 6:820–837

194 Strohl WR (2009) Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20:685–691

195 Strohl WR (2011) Isotype selection and Fc engineering: design and construction of fit-for-purpose therapeutic antibodies. In: Wood C (ed) Antibody drug discovery. Imperial College Press, London, pp 147–220

196 Strohl WR (2015) Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29:215–239

197 Strohl WR, Strohl LM (2012). Therapeutic antibody engineering: current and future advances driving the strongest growth area in the pharma industry. Woodhead Publishing Series in Biomedicine No. 11 (Cambridge). ISBN 9781907568374. Published Oct 22, 2012

198 Strop P, Ho W-H, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T (2012) Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 420:204–219

199 Sun L-M, Liu Y-C, Li W, Liu S, Liu H-X, Li L-W, Ma R (2017) Nivolumab effectively inhibit platinum- resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression. Eur Rev Med Pharmacol Sci 21:1198–1205

200 Suzuki M, Curran KJ, Cheung N-KV (2015) Chimeric antigen receptos and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer 62:1326–1336

201 Tanoue K, Shaw AR, Watanabe N, Porter C, Rana B, Gottschalk S, Brenner M, Suzuki M (2017) Armed oncolytic adenovirus expressing PD-L1 mini-body enhances anti-tumor effects of chimeric antigen receptor T-cells in solid tumors. Cancer Res 77:2040–2051

202 Taylor RP, Lindorfer MA (2016) Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of antitumor monoclonal antibodies. Semin Immunol 28:309–316

203 Teicher BA (2009) Antibody-drug conjugate targets. Curr Cancer Drug Targets 9:982–1004

204 Thompson P, Ezeadi E, Hutchinson I, Fleming R, Bezabeh B, Lin J, Mao S, Chen C, Masterson L, Zhong H (2016) Straightforward glycoengineering approach to site-specific antibodypyrrolobenzodiazepine conjugates. ACS Med Chem Lett 7:1005–1008

205 Throsby M, Logtenberg T, De Kruif J(2015) Generation of binding molecules. US 9145588 B2, Published Sept 29, 2015

206 Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450–561

207 Tsuchikama K, An Z (2016) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell (this issue)

208 Tustian AD, Endicott C, Adams B, Mattila J, Bak H (2016) Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. mAbs 8:828–838

209 Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999) Engineered glycoforms of an anti- neuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17:176–180

210 Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia T, Strohl WR (2013) An engineered silent Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 65:114–126

211 van der Stegen SJC, Hamieh M, Sadelain M (2015) The pharmacology of second-generation chimeric antigen recpetors. Nat Rev Drug Discov 14:499–509

212 van der Vlist M, Kuball J, Radstake TRD, Meyaard L (2016) Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?Nat Rev Rheumatol 12:593–604

213 Von Kreudenstein TS, Escobar-Carbrera E, Lario PI, D’Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH, Girod PA, Suits MD, Boulanger MJ, Poon DK, Ng GY, Dixit SB (2013) Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. mAbs 5:646–654

214 Walker MR, Lund J, Thompson KM, Jefferis R (1989) Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing FcγRI and/or FcγRII receptors. Biochem J 259:347–353

215 Wang Y, Yan Z, Huang Y, Qiu C, Chen X, Hu Y, Meng Q, Wei J (2017a) Study of natural antibodies against vascular endothelial growth factor receptor 1 in hepatocarcinoma. Am J Cancer Res 7:603–609

216 Wang B, Kothambawala T, Hinton P, Ng D, Saini A, Baliga R, Keyt B (2017b) Multimeric anti-DR5 IgM antibody displays potent cytotoxicity in vitro and promotes tumor regression in vivo. Abstract no 1702 AACR Ann Meet 2017, April 1–5, 2017

217 Ward ES, Güssow D, Griffiths AD, Jones PT, Winter G (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544–546

218 Webster CI, Caram-Salas N, Haqqani AS, Thom G, Brown L, Rennie K, Yogi A, Costain W, Brunette E, Stanimirovic DB (2016) Brain penetration, target engagement, and disposition of the bloodbrain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1. FASEB J 30:1927–1940

219 Wu C, Ting H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25:1290–1297

220 Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K (2004) Establishment of FUT8 knockout Chinese hamster ovary cells; an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody- dependent cellular cytotoxicity. Biotechnol Bioeng 87:614–622

221 Yang L, Wang P (2014) Passive immunization against HIV/AIDS by antibody gene transfer. Viruses 6:428–447

222 Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS (2011) Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Trans Med 3:84ra44

223 Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ (2014) Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Trans Med 6:261ra154. 3009835

224 Yurkovetskiy AV, Yin M, Bodyak N, Stevenson CA, Thomas JD, Hammond CE, Qin LL, Zhu B, Gumerov DR, Ter-Ovanesyan E (2015) A polymer-based antibody-vinca drug conjugate platform: characterization and preclinical efficacy. Cancer Res 75:3365–3372

225 Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:157–159

226 Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubel S, Schmitt B, Lindhofer H (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163:1246–1252

227 Zeltsman M, Mayor M, Jones DR, Adusumilli PS (2016) Surgical immune interventions for solid malignancies. Am J Surg 212:682–690

228 Zhang X-Y, Zhang P-Y (2016) Receptor tyrosine kinases in carcinogenesis (Review). Oncol Lett 12:3679–3682

229 Zhou Y, Zou H, Zhang S, Marks JD (2010) Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast displayed tumor antigens. J Mol Biol 404:88–99

230 Zhukovsky EA, Morse RJ, Maus MV (2016) Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol 40:24–35